About edwards lifesciences corp. - EW
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
EW At a Glance
Edwards Lifesciences Corp.
1 Edwards Way
Irvine, California 92614
| Phone | 1-949-250-2500 | Revenue | 6.07B | |
| Industry | Medical Specialties | Net Income | 1.06B | |
| Sector | Health Technology | 2025 Sales Growth | 11.547% | |
| Fiscal Year-end | 12 / 2026 | Employees | 16,000 | |
| View SEC Filings |
EW Valuation
| P/E Current | 45.682 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 47.107 |
| Price to Sales Ratio | 8.231 |
| Price to Book Ratio | 4.789 |
| Price to Cash Flow Ratio | 31.31 |
| Enterprise Value to EBITDA | 25.977 |
| Enterprise Value to Sales | 7.65 |
| Total Debt to Enterprise Value | 0.015 |
EW Efficiency
| Revenue/Employee | 379,225.00 |
| Income Per Employee | 66,256.25 |
| Receivables Turnover | 6.652 |
| Total Asset Turnover | 0.454 |
EW Liquidity
| Current Ratio | 3.716 |
| Quick Ratio | 3.095 |
| Cash Ratio | 2.33 |
EW Profitability
| Gross Margin | 77.914 |
| Operating Margin | 26.869 |
| Pretax Margin | 20.979 |
| Net Margin | 17.471 |
| Return on Assets | 7.925 |
| Return on Equity | 10.426 |
| Return on Total Capital | 9.60 |
| Return on Invested Capital | 9.773 |
EW Capital Structure
| Total Debt to Total Equity | 6.824 |
| Total Debt to Total Capital | 6.388 |
| Total Debt to Total Assets | 5.15 |
| Long-Term Debt to Equity | 6.587 |
| Long-Term Debt to Total Capital | 6.166 |
Edwards Lifesciences Corp. in the News
Medical-device makers gain amid return to normalcy
Many of the top large-cap device makers reported relatively rosy fourth-quarter earnings while issuing 2023 guidance that was above analyst expectations.